bluebird bio Brings in $30M to Advance Gene Therapies
By Catherine Schaffer
Wednesday, April 20, 2011
A little over a year after its $35 million Series B financing, bluebird bio has returned for another $30 million, laying down a three-year cash runway for advancement of its gene therapy products for rare diseases. CEO Nick Leschly calls the financing, which brings in new investor ARCH Venture Partners, "opportunistic." Existing investors Third Rock Ventures, TVM Capital, Forbion Capital Partners and Easton Capital Investment Group also participated.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.